Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma
Chong Wu(Sun Yat-sen University), Limin Zheng(Weifang University of Science and Technology), Jing Liao(Guangzhou Medical University), Shi‐Mei Zhuang(Sun Yat-sen University), Jinhua Huang(Sun Yat-sen University), Shufeng Luo(Central South University), Li Xu(Jiangxi University of Traditional Chinese Medicine), Jian Zhou(Shenzhen University Health Science Center), Cheng Sun(Tianjin Third Central Hospital), Jie Lin, Mingyu Liu(General Hospital of Guangzhou Military Command), Chao Liu(Sun Yat-sen University), Jing Xu(University of Chicago), Jinqing Li(Sun Yat-sen University), Chaoqun Liu(Beijing University of Chinese Medicine), Minshan Chen(Sun Yat-sen University), Zhenhong Guo(Second Military Medical University), Qiaomin Hua(Biocon (Switzerland)), Dan-Ni Zeng(Biocon (Switzerland)), Yulan Weng(Biocon (Switzerland))
Cited by 82
Related Papers
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
|Cell Metabolism|2020|1.7k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
|Liver Cancer|2020|828